Quince’s transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of ...
COPENHAGEN (November 19, 2025)—New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next ...
SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results